Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chimeric antigen receptor and car-t cells that bind bcma

A chimeric antigen receptor, B cell technology, applied in genetically modified cells, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antibody, etc.

Pending Publication Date: 2019-04-16
MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
View PDF42 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, rituximab seems unsuitable for this treatment because its target antigen, CD20, is not expressed on plasma cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor and car-t cells that bind bcma
  • Chimeric antigen receptor and car-t cells that bind bcma
  • Chimeric antigen receptor and car-t cells that bind bcma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0309]Multiple myeloma, also known as plasmacytoma, is a currently incurable B-cell lymphoma that arises from malignantly transformed plasma cell clones. The disease is the most common tumor in the bone and marrow, with a median life expectancy of 7 years and 2% of cancer deaths each year. Malignant transformation is thought to occur in the germinal centers of secondary lymphoid organs at developmental stages, where B cells have undergone VDJ rearrangement and isotype switching. The median age at diagnosis is 70 years, suggesting that in many patients there are comorbidities that would make aggressive and long-term chemotherapy or radiation therapy unsuitable. In addition, this patient population is usually not a candidate for allogeneic bone marrow transplantation. The clinical features of the disease are osteolytic lesions, hypercalcemia, hematopoietic insufficiency, amyloid deposition, renal failure, excess antibody heavy and / or light chain production, hyperviscosity, infe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a B Cell Maturation Antigen (BCMA) polypeptide. The CAR preferably binds an epitope comprising one or more amino acids of residues 13 to 32 of the N-terminus of human BCMA. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic B cells, such as a disease of plasma cells, memory B cells and / or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody- dependent autoimmune diseases.

Description

technical field [0001] The present invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen binding domain comprising an antibody or antibody fragment that binds a B cell maturation antigen (BCMA) polypeptide. The CAR preferably binds to an epitope comprising one or more amino acids in the N-terminal residues 13 to 32 of human BCMA. The invention also relates to nucleic acid molecules encoding the CARs of the invention, genetically modified immune cells (preferably T cells) expressing the CARs of the invention, and the use of said cells in the treatment of medical conditions associated with the presence of pathogenic B cells Use for medical conditions such as diseases of plasma cells, memory B cells and / or mature B cells, in particular multiple myeloma, non-Hodgkin's lymphoma or autoantibody-dependent autoimmune diseases. Background technique [0002] In cancer immunotherapy, adoptive transfer of T cell...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/17C07K16/28
CPCA61K35/17C07K16/2878A61K2039/505C07K2317/24C07K2317/33C07K2317/34C07K2317/622C07K2317/73A61P19/02A61P29/00A61P35/00A61P37/00A61P37/02A61P37/06C12N5/0636C07K2319/03C12N2510/00A61K47/65C07K14/70596C12N15/62C12N15/85
Inventor 阿明·雷姆乌塔·伊丽莎白·霍普肯尤利娅·布卢姆沃尔夫冈·乌克特埃莉萨·基巴克斯蒂芬·马里诺
Owner MAX DELBRUECK CENT FUER MOLEKULARE MEDIZIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com